Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
University of Medicine and Dentistry of New Jersey
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01789255CT.gov Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | — | Completed | — | — | — |
NCT01384513CT.gov A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | — | Completed | — | — | — |
NCT00489203CT.gov Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Refractory Hairy Cell Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tacrolimus (this asset) | University of Medicine and Dentistry of New Jersey | P2 | BB · 68 |
| Fludarabine | Case Comprehensive Cancer Center | P2 | BBB |
| Cyclosporin A | National Cancer Institute (NCI) | P2 | BB |
| Cediranib | National Cancer Institute (NCI) | P2 | BB |
| Rituximab | Mayo Clinic | P2 | BB |
| Cyclophosphamide | Case Comprehensive Cancer Center | P2 | BB |
| Romidepsin | Mayo Clinic | P2 | BB |
| Lenalidomide | Joseph Tuscano | P2 | BB |
| Dexasone | City of Hope Medical Center | P2 | BB |
+42 more in the Refractory Hairy Cell Leukemia cohort
Other indications for Tacrolimus
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Disease Related To Transplantation | — | P4 | BBB · 79 |
| Disease Related To Solid Organ Transplantation | — | P4 | BBB · 76 |
| Beta-Thalassemia Major | — | P4 | BBB · 75 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tacrolimus in Refractory Hairy Cell Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tacrolimus-refractory-hairy-cell-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →